Bellicum Announces Data Presentations at the Annual Meetings of the American Society of Clinical Oncology and the European Hematology Association
Also in June, data from the ongoing BP-004 clinical trial of BPX-501,
the Company’s adjunct T cell therapy for allogeneic hematopoietic stem
cell transplantation, will be discussed by Dr.
ASCO Presentation Details:
Presentation Title: “Enhanced efficacy and safety of
Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40
costimulation and iCaspase-9 suicide switch”
Abstract Number:
3050
Poster Board: #372
Session Name:
Developmental Therapeutics - Immunotherapy
Date:
Presentation Time:
EHA Oral Presentation Details:
Presentation Title: “Infusion of BPX-501 (donor T cells
transduced with the iC9 suicide gene) after α/β T-cell depleted
haplo-HSCT in children with acute leukemia: Preliminary results of a
Phase I-II trial”
Abstract Number: S523
Session Name:
Stem cell transplantation - Clinical 1
Date:
Presentation Time:
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Forward-Looking Statement
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue," “designed,”
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
research and development activities relating to rimiducid, CID, CAR,
TCR, MyD88/CD40 and iCaspase9; the effectiveness of rimiducid and of
BPX-501, their possible range of application and potential curative
effects and safety in the treatment of diseases; the timing and success
of our clinical trials, including our BP-004 clinical protocol; the
timing of regulatory filings for BPX-501 and for rimiducid; our research
and development activities relating to BPX-501 and rimiducid; and the
potential applications and effectiveness of our product candidates
BPX-501 and rimiducid, including as compared to other treatment options
and competitive therapies. Various factors may cause differences between
Bellicum’s expectations and actual results as discussed in greater
detail under the heading “Risk Factors” in Bellicum’s filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160519005593/en/
Source:
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso,
832-384-1116
CFO
amusso@bellicum.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
